We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Throughout the year, you will have the opportunity to participate in campaigns that support endocrinology research, care, professionals, and patients. Contact us to get more involved: advocacy@endocrine.org.
Taking action by sending messages to your Congressional delegation makes a difference, and our online campaigns make it easy to do. Don't take it from us, hear from Rosa DeLauro, Ranking Member of the House Appropriations Committee, why your voice matters.
On September 30, Congress passed short-term legislation that will fund the Federal government, including the NIH, at current levels. The Continuing Resolution (CR) will last 45 days, until November 17. Time is running out for Congress to complete the appropriations process. The Endocrine Society is advocating for a full-year funding bill with increases for NIH. We know our advocacy has influence. It is critical that your Representatives and Senators hear from you.
Congress was able to pass a last-minute Continuing Resolution (CR), funding the Federal government at current levels until November 17. This bill also included a short-term extension to the Special Diabetes Program. However, funding for SDP will end on November 17 unless Congress passes legislation to provide long term extension of the program. SDP is a federal program comprised of two components – the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians. Congress created these programs in 1997 to advance research for type 1 diabetes at the NIDDK and to provide treatment and education programs for type 2 diabetes among American Indians and Alaska Natives. The Endocrine Society is advocating for a two-year extension and a 13% funding increase for this important program. It is critical that members of Congress hear from you.
Obesity has damaged our nation’s health, and its prevalence is increasing: over 42% of US adults and over 19% of children are estimated to have obesity. The Endocrine Society is urging the U.S. House of Representatives and Senate to pass the Treat and Reduce Obesity Act (TROA). This legislation would allow coverage of anti-obesity medications (AOMs) currently prohibited in the Medicare statute and expand access to intensive behavioral therapy (IBT) for obesity. It is critical that your Senators and Representatives hear from you on the importance of passing this legislation.
The Endocrine Society is urging the Senate to pass the bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act. Last year, President Biden signed the Inflation Reduction Act into law, which capped insulin costs for Medicare beneficiaries. However, insulin remains unaffordable for people with private insurance. Join our campaign today to remind your Senators that addressing insulin affordability for people with private insurance is a top priority.
Congress is in the process of determining funding for the National Institutes of Health (NIH) in fiscal year (FY) 2024. This will affect all researchers who receive grant funding from NIH. To protect NIH from severe cuts, it is critical that your Representative and Senators hear from you about this issue.
Read our newsletters covering the latest science-based information on endocrine-disrupting chemicals (EDCs) for policymakers in the European Union.
